TORONTO, April 20, 2017 /CNW/ - Medicenna Therapeutics Corp. (TSXV: "MDNA") ("Medicenna" or "the Company"), a publicly listed clinical stage immuno-oncology company, today announced that executives from Medicenna, Dr. Fahar Merchant and Ms. Elizabeth Williams, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference May 1-2, 2017. Medicenna recently treated its first patient in a Phase 2b trial of MDNA55 for recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.
The presentation will take place on Monday May 1st at 10:00am Eastern time in Hall B of the Sheraton Centre Toronto Hotel in Toronto, Canada and will be webcast at http://wsw.com/webcast/bloomburton2/mdna.
Medicenna is a publicly listed (TSXV: "MDNA") clinical stage immuno-oncology company developing novel, highly selective engineered versions of IL-2, IL-4 and IL-13 cytokines called Superkines™ and first in class Empowered Cytokines™ (ECs). Medicenna is specifically targeting the Interleukin-4 Receptor, which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL‐4EC, MDNA55, is enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGB), the most aggressive and common form of brain cancer. MDNA55 has completed three clinical trials in 66 patients with rGB, demonstrated promising efficacy and obtained Fast-Track Designation from the USFDA and Orphan Drug status from the USFDA and EMA. Unlike most other cancer therapies, Medicenna's IL-4 ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients. For more information, please visit www.medicenna.com.
About the Conference
Bloom Burton & Co. is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. We aim to showcase approximately sixty of the premier Canadian healthcare companies to our network of investors, who generally join us from across Canada, the U.S. and Europe. We will have networking sessions, keynote speeches and panel discussions with venture capital, public equity and strategic investors. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in our 1-on-1 meeting system with company management.
About Bloom Burton & Co.
Bloom Burton & Co. is a firm dedicated to accelerating returns in healthcare for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF). Please visit www.bloomburton.com to learn more.
This news release contains forward-looking statements. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding future plans and objectives of the Company and others are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the filing statement of the Company dated February 27, 2017 and in other filings made by the Company with the applicable securities regulators from time to time.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.
For further information: Company Contacts: Fahar Merchant, Chairman, President & Chief Executive Officer, Medicenna Therapeutics Corp., 604-671-6673, firstname.lastname@example.org; Elizabeth Williams, Chief Financial Officer, Medicenna Therapeutics Corp., 416-648-5555, email@example.com